8 recruiting, 4 completed, 3 active not recruiting, 2 unknown. 11 Phase 2, 6 Phase 1, 1 Early Phase 1, 1 Not applicable.
Follow Borderline Resectable Pancreatic Adenocarcinoma: new trials by email Literature Review of Borderline Resectable Pancreatic Adenocarcinoma trials Research Report on Borderline Resectable Pancreatic Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation HRS-4642+AG+Nimotuzumab - Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Zhejiang University | 40 | 2026-02-15 | 2026-02-13 |
| IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer IBI343 - Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 40 | 2026-02-01 | 2026-02-17 |
| A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer Standard Reagents, Pancreatic Cancer - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Recruiting | Ruijin Hospital | 119 | 2025-05-20 | 2025-07-29 | |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) PTM-101 - Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 | Recruiting | PanTher Therapeutics | 26 | 2025-04-14 | 2026-10-08 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, Radiological Assessments - Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Wake Forest University Health Sciences | 64 | 2023-08-01 | 2026-09-28 |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study Cisplatin, Fluorouracil, Gemcitabine - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-04-18 | 2026-05-04 | |
| Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery - Pancreatic Neoplasm, Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Erasme University Hospital | 256 | 2023-03-24 | 2023-05-23 |
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Biospecimen Collection, Computed Tomography, Core Biopsy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 56 | 2023-03-07 | 2026-10-29 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer Pancreas Cancer, Pancreas Neoplasm | Recruiting | Umeå University | 300 | 2022-04-19 | 2022-11-30 | |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Durvalumab, Gemcitabine, Nab-paclitaxel - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 13 | 2021-09-28 | 2026-10-07 |
| Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma Stereotactic Ablative Body Radiotherapy (SABR) - Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Not applicable | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 30 | 2021-08-01 | 2021-06-22 |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer Paclitaxel protein bound, Gemcitabine, Cisplatin - Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 19 | 2020-12-01 | 2026-07-21 |
| NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2020-07-01 | 2026-05-22 |
| Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer Hypofractionated Radiation Therapy, Losartan, Losartan Potassium - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | University of Utah | 22 | 2019-08-08 | 2026-07-06 |
| Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer Fluorouracil, Irinotecan, Irinotecan Hydrochloride - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 28 | 2019-07-24 | 2024-08-09 |
| Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) Folfirinox - Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect | Active not recruiting | Oslo University Hospital | 251 | 2018-01-01 | 2024-11-20 | |
| Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 25 | 2015-11-12 | 2022-09-02 |
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy - Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Unknown | Candel Therapeutics, Inc. | 54 | 2015-10-01 | 2024-01-08 |
Pancreatic Neoplasms (8) · Pancreatic Diseases (1)
Digestive System Diseases (8) · Digestive System Neoplasms (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Pancreatic Diseases (7)
Fluorouracil (5) · Gemcitabine (5) · Leucovorin (5) · Taxes (5) · Irinotecan (4) · Oxaliplatin (4) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Radiation (3) · Radiotherapy (3) · Surgical Procedures, Operative (3) · dehydroftorafur (3) · Chemoradiotherapy (2) · Cisplatin (2) · folfirinox (2)
M.D. Anderson Cancer Center (4) · Jonsson Comprehensive Cancer Center (2) · Zhejiang University (2) · Amsterdam UMC, location VUmc (1) · Candel Therapeutics, Inc. (1) · Erasme University Hospital (1) · HonorHealth Research Institute (1) · Kimberly Perez, MD (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Oslo University Hospital (1) · PanTher Therapeutics (1) · Ruijin Hospital (1) · Umeå University (1) · University of Utah (1) · Wake Forest University Health Sciences (1)
United States (11) · China (3) · Australia (1) · Belgium (1) · Mexico (1) · Netherlands (1) · Norway (1) · Sweden (1)
Eugene J Koay (2) · Zev A Wainberg (2) · Brandon G Smaglo (1) · Christelle Bouchart, MD (1) · Erkut Borazanci, MD (1) · Eugene J Koay, MD,PHD (1) · Jean-Luc Van Laethem, MD (1) · Kimberly Perez, MD (1) · Knut J. Labori, MD, PhD (1) · Ravi K Paluri, MD, MPH (1) · Shane Lloyd (1)
PMID 34980020, PMID 35863672, PMID 37735634, PMID 38126766, PMID 38155512, PMID 38957079
2023 (1), P30CA012197 (1)